



APPENDIX 4D

1. Name of Entity **CardieX Limited**
ACN 113 252 234

Half year ended 31 December 2019
Reporting period 1 July 2019 to 31 December 2019
Previous period 1 July 2018 to 31 December 2018

2. Results for announcement to the market

	31 December 2019 \$	31 December 2018 \$	% Change Up (Down)
2.1 Revenues from continuing operations	2,302,757	2,007,925	15%
2.2 Loss from continuing operations after tax attributable to members	(1,965,395)	(1,365,391)	44%
2.3 Net loss attributable to members	(1,943,756)	(1,410,144)	38%
2.4 Proposed dividends	Nil	Nil	-
2.5 Record date for dividend entitlement	N/A	N/A	-
2.6 Revenues for the period increased on a year on year basis. Whilst the loss for the period has increased by \$600,004 as compared to the previous period, the increase in net loss is largely attributable to expenditure in relation to expansion and diversification into new projects and product development initiatives as reported to the market.			

Not included in revenue for the half year is \$965,164 in unearned contract liabilities, including \$918,359 from Bayer, for which cash receipts is expected within 3 months of financial year end and be recognised in revenue in the next 12 months.

	31 December 2019 Cents	30 June 2019 Cents	% Change Up (Down)
3. Net tangible asset per security*	0.91 cents	1.00 cents	(9%)

* Right of Use Assets are included in the NTA calculations

4. The Group gained a new Chinese controlled entity in the period, which is CardieX (Shanghai) Medical Technology Co., Ltd.
5. There were no payments of dividends during the reporting period.
6. There is no dividend reinvestment plan in operation.

7. There are no associates or joint venture entities.
8. The Company is not a foreign entity.
9. The accounts are not subject to any audit dispute or qualification.

The Company's half year report follows.

Yours sincerely,



Jarrod White

Chief Financial Officer
28 February 2020

For further information, please contact:

Jarrod White
Chief Financial Officer

jwhite@cardiex.com

Investor Relations

Peter Taylor

+61 412 036 231

peter@nwrcommunications.com.au

About Cardiex

Cardiex Limited is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. Cardiex also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating Cardiex technology. In November 2018 Cardiex entered into an agreement with telehealth services provider, inHealth Medical Services, Inc, allowing Cardiex to acquire up to 50.5% of inHealth by way of a convertible note.